McKesson (MCK) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for McKesson (MCK) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
McKesson (MCK) Surpasses Q2 Earnings Estimates
McKesson (MCK) came out with quarterly earnings of $9.86 per share, beating the Zacks Consensus Estimate of $8.92 per share. This compares to earnings of $7.07 per share a year ago.
Will Strong Segmental Performance Drive MCK's Top Line in Q2?
McKesson's Q2 results may show steadier growth as strong U.S. pharmaceutical and RxTS momentum drive its expanding top line.
Ahead of McKesson (MCK) Q2 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Beyond analysts' top-and-bottom-line estimates for McKesson (MCK), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2025.
McKesson (MCK) Reports Next Week: Wall Street Expects Earnings Growth
McKesson (MCK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
McKesson (MCK) Upgraded to Strong Buy: Here's What You Should Know
McKesson (MCK) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
McKesson (MCK) Surpasses Market Returns: Some Facts Worth Knowing
McKesson (MCK) reached $801.67 at the closing of the latest trading day, reflecting a +1.1% change compared to its last close.
McKesson (MCK) Surpasses Market Returns: Some Facts Worth Knowing
McKesson (MCK) reached $786 at the closing of the latest trading day, reflecting a +1.36% change compared to its last close.
McKesson (MCK) Ascends While Market Falls: Some Facts to Note
In the closing of the recent trading day, McKesson (MCK) stood at $781.9, denoting a +1.61% move from the preceding trading day.
Here's Why McKesson (MCK) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
McKesson Corporation Transforming Towards High-Margin Operations: Why I Choose To Buy
McKesson Corporation is transforming from a traditional distributor to a tech-enabled healthcare services leader, focusing on high-margin specialty and digital solutions. Recent acquisitions (PRISM Vision, Core Ventures) and organizational restructuring position MCK for sustained growth in oncology, multispecialty, and technology-enabled segments. Q1 FY26 results showed strong revenue growth, robust cash flow guidance, and raised long-term EPS targets, reflecting confidence in durable earnings momentum.
McKesson: Strategic Shift To High-Growth Oncology And Prescription Tech Signals Long Opportunity
McKesson Corporation is rated 'Buy' due to its transformation into a higher-growth, higher-margin healthcare services platform focused on Oncology & Multispecialty and Prescription Technology Solutions. MCK's upgraded long-term adjusted EPS growth target of 13%-16%, aggressive capital returns, and strategic realignment support a bullish outlook and potential for significant stock price appreciation by FY2030. Key risks include regulatory pressure on U.S. drug pricing, opioid litigation overhangs, execution risks in acquisitions and divestitures, and high customer concentration, which may cause volatility or corrections.
